A New Year, but the Same Old Stock Market
The new year was to have brought a new beginning for China's stock market. Instead, investors who were set to welcome the return of IPO action after a suspension of 14 months were disappointed by news on January 10 that Jiangsu Aosaikang Pharmaceutical Co. Ltd. was putting its anticipated initial public offering on hold.
The abrupt postponement has sparked questions about the regulator's reform agenda. Clearly, at a time when it is trying to clarify its own role vis-à-vis the market, the regulator has yet to master the art of timing. Xiao Gang, chairman of the China Securities Regulatory Commission, said at a work conference this month that reform will see a complete overhaul of the regulator's scope of oversight of the capital market. Its recent actions must be seen in light of this pledge.
- Holiday Days
- The China Boom: Why China Will Not Rule the World
- One Point Two Billion
- Ailing Northeast Struggles to Keep Young Talent
- Much Has Changed Since Short Sellers Last Attacked HK Dollar
- Day of Play
- Software Firms Accuse Alibaba Health Subsidiary of Profiteering
- Inquiry into Guangdong Official 'Linked to Helping Sex Industry'
- Medical Fees Proposal Jolts China's Pensioners
- Sign up to receive our free daily newsletter
- China Now Learning It Has 'Environmental Migrants'
- Internet Company Treats 2,000 Employees to Cruise as Holiday Present
- Alibaba Gets Bitter Pill as Gov't Said to Scrap E-Drug System
- Government Edges toward Promised Tax Reform
- Carmaker BYD Fares Well in Hometown, Struggles Elsewhere
- Caixin OnlineAnother Official Tied to Zhou Yongkang Is Handed Jail Term
- U.S. Venture Capital Firm Is Still Betting on China
- More Insiders Said to Be Linked to Agricultural Bank Scandal
- Five Major Economic Risks to Watch for This Year
- Manufacturing Slows Again to Start 2016, with Caixin China PMI at 48.4